Clinical Trial: Blood Samples From Patients on a Clinical Trial to CINV During HSCT
Study Status: Terminated
Recruit Status: Terminated
Study Type: Observational
Official Title: Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation
Brief Summary:
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about nausea and vomiting caused by cancer treatment.
PURPOSE: This laboratory study is looking at blood samples from patients with cancer who were treated on a clinical trial to control nausea and vomiting during donor stem cell transplant.
Detailed Summary:
OBJECTIVES:
Primary
- To compare the amount of substance P in serum samples from patients with cancer treated with busulfan/cyclophosphamide or cyclophosphamide/total body irradiation conditioning regimens prior to undergoing allogeneic hematopoietic stem cell transplantation.
Secondary
- To assess the changes in substance P over time to see if there is an optimal time shown by this physiologic correlate to discontinue substance P blockade after the chemotherapy regimen is completed in these patients.
OUTLINE: Previously collected serum samples are analyzed by enzyme immunoassay for changes in substance P levels.
Patients' medical records are reviewed for demographic information, past history, and course of treatment.
Sponsor: OHSU Knight Cancer Institute
Current Primary Outcome: Average, median, and mode for substance P levels at different times
Original Primary Outcome: Same as current
Current Secondary Outcome: Correlation of substance P levels with patient response (emesis or not)
Original Secondary Outcome: Same as current
Information By: OHSU Knight Cancer Institute
Dates:
Date Received: May 9, 2009
Date Started: August 2008
Date Completion:
Last Updated: May 7, 2017
Last Verified: May 2017
